We examined whether immunization with a newly developed oral cholera vaccine would elicit gut-derived antibody-producing cells in the blood and in distant mucosal tissues, such as the minor salivary glands, in 30 adult Swedish volunteers. The results of this study demonstrated that this vaccine indeed induced production of specific antibody-producing cells against the cholera toxin B subunit in both peripheral blood and salivary glands. The response in blood, which after primary and booster immunizations comprised both immunoglobulin A (IgA) and IgG antibody-forming cells, was highly transient and preceded the response in salivary glands; the latter response was restricted to the IgA isotype. The results provide further evidence of the existence of a common mucosal immune system in humans. Furthermore, these findings support previous observations that in animals, the cholera toxin B subunit may be a useful carrier protein for preparing enteric vaccines against pathogens encountered at intestinal and extraintestinal mucosal sites.
Mucosal surfaces of the alimentary tract represent the largest anatomical separation between internal organ systems and the external environment. The intestinal mucosa encounters a wide variety of antigens, and it is not surprising that lymphoid tissues in the intestinal wall represent the largest lymphoid mass in the body (4) . The fact that discrete populations of intestinal lymphoid cells have a predilection to migrate and to localize not only to the intestine but also to other distant mucosal sites (1) emphasizes the strategic importance of gut-associated lymphoid tissues in the overall immune apparatus. These migratory pathways have formed the basis for the concept of a generalized mucosal immune system (2) . The most convincing evidence in support of this concept has been provided by adoptive transfer experiments in which B lymphocytes from mucosa-associated lymphoid tissues have been shown to repopulate various secretory tissues of syngeneic animals with immunoglobulin A (IgA)-producing cells (5, 19, 27, 38) .
Although ingestion of microbial antigens is known to induce the concomitant appearance of secretory antibodies in various human secretions (6, 12, 22, 36) , evidence for the existence of a common mucosal immune system in humans remains indirect (reviewed in reference 20) .
In the present study, we demonstrate the sequential appearance of antibody-producing cells in the circulatory system and in the salivary glands of orally immunized human volunteers. The model antigen used for these studies consists of the B subunit protein of cholera toxin (CT) and is an important component of a recently developed oral vaccine against cholera (14, 33) . This vaccine was chosen both because of its well-established ability to stimulate a strong secretory intestinal immune response in humans (34) and because of its ability to concomitantly evoke an immune response in the salivary glands of animals (11 (14) , each dose consisting of 1 mg of purified CT B subunit and 1 x 1011 killed cholera vibrios administered in 150 ml of alkalinizing buffer (bicarbonate) (31) . The time interval between each dose was 2 weeks. The vaccine was produced by Institut Merieux (Lyon, France), and the B subunit was prepared according to previously published large-scale purification protocols (35) . The vaccine used in this study was of the same lot that has been extensively tested in a large field trial in Bangladesh (31) . Samples of unstimulated parotid saliva (9, 22) (8, 28) . Individual wells of nitrocellulose-coated 96-well Millititer hemagglutination plates (Millipore, Bedford, Mass.) were coated with GM1 ganglioside (3 nM/ml, overnight at 4°C), washed 3 times with PBS, and further exposed for 3 h at ambient temperature to 0.1 ml of PBS containing 2.5 ,ug of purified CT (List Biological Laboratories, Inc., Campbell, Calif.) or 10 jig of bovine serum albumin (control wells). Unadsorbed proteins were removed by three successive washings with PBS, and the wells were filled with 0.2 ml of PBS containing 1% FCS and incubated at 37°C for 2 h. The contents of the wells were replaced with 0.1 ml of cell suspensions containing various numbers of MNC. Plates were then incubated undisturbed for 16 h at 37°C in a humidified atmosphere with 7% CO2. Plates were then rinsed three times with PBS and four times with PBS containing 0.05% Tween 20. Next, 0.1 ml of PBS-0.05% Tween 20 containing 1% FCS and either a mixture of affinity-purified goat anti-human IgG (0.8 ,ug/ml) and goat anti-human IgA (1.6 jig/ml) antibodies conjugated with alkaline phosphatase and horseradish peroxidase, respectively, or a mixture of affinity-purified alkaline phosphatase-conjugated goat antihuman IgA (0.8 ,ug/ml) and horseradish peroxidase-conjugated anti-human IgM (1 j,g/ml) antibodies were added to the wells. All enzyme-conjugated antiglobulin reagents were purchased from Southern Biotechnology Associates (Birmingham, Ala.), and their specificities were confirmed by ELISA block titrations against a panel of human IgA and IgM paraproteins (gifts from Jiri Mestecky, University of Alabama at Birmingham) and purified human polyclonal IgG. Plates were incubated with enzyme-conjugated antiglobulins for 2 to 3 h at ambient temperature and washed four times with PBS and twice with 0.05 M Tris-buffered saline, pH 8.0. Wells were then decanted and exposed to 0.1 ml of alkaline phosphatase chromogen substrate for 10 to 20 min, washed with PBS, and exposed to 0.1 ml of horseradish peroxidase chromogen substrate for 5 to 10 min (7). Dishes were thoroughly rinsed with tap water, dried, and examined for the presence of blue (alkaline phosphatase) and red (horseradish peroxidase) spots. These reactions were enumerated under low magnification (x40). Numbers of spotforming cells (SFC) were determined on duplicate (for salivary gland suspensions) or quadruplicate (for peripheral blood suspensions) wells and adjusted to numbers of SFC per 106 MNC.
Total IgA-, IgG-, and IgM-secreting cells were similarly enumerated in wells previously coated with affinity-purified goat antibodies to the F(ab')2 fragment of human IgG (5 ,ug/ml) (Jackson Immunoresearch Laboratories, Inc., West Grove, Pa.).
Exposure of cell suspensions to cycloheximide (2 x 10-3 M) for 3 h at 37°C before and during cell plating abrogated CT-specific as well as total immunoglobulin-mediated spot formation, thus demonstrating that this assay detects cells synthesizing and actively secreting immunoglobulins.
ELISAs. Serum and parotid saliva samples were assayed by ELISA for levels of IgA and IgG antibodies to CT attached to GM1 gangliosides, as previously described (32) .
RESULTS
Circulating antibody responses to oral cholera vaccine. We examined whether single or repeated oral immunizations with the B subunit-containing cholera vaccine would elicit an antitoxin SFC response in peripheral blood and to what extent the magnitude, kinetics, and isotype distribution of this response corresponded to the antibody response in serum and to the responses in salivary glands and in parotid saliva (see below). The serological analyses showed that in all vaccinees, a significant serum antitoxin antibody response developed after the first immunization (Table 1) . This response was slightly increased by a second and third immunization. Antibodies of the IgG isotype predominated in the serological responses of all individuals, showing a 6-fold geometric mean increase in titer from preimmunization levels after the first oral dose of cholera vaccine and showing 10-and 12-fold increases after the second and third immunizations, respectively. In the majority of volunteers, the oral cholera vaccination also induced an IgA antitoxin response in serum. Kinetically, the IgA response followed the IgG response but was of a lower magnitude and occurred less frequently than the IgG response ( Table 1 ). The geometric mean increases in titer of serum IgA antitoxin antibody responses after the first, second, and third immunizations were 1.3-, 4.0-, and 10-fold, and the increases in frequency of responses were 15, 50, and 75%, respectively.
The SFC responses in peripheral blood differed sharply from the serological responses with regard to kinetics and isotype distribution (Fig. 1) . While the serum antibody titers were not significantly increased until 2 weeks after the first immunization, SFC responses were already manifest 1 week after primary immunization and then decreased to almost background level after another week. This kinetically dramatic SFC response with a brisk but transient elevation in SFC was then repeated and slightly enlarged after each of the booster immunizations (Fig. 1) . Also in contrast to the serological response, the frequencies of IgA and IgG SFC were comparable. In no instance could IgM SFC be detected in the peripheral blood of oral cholera vaccinees throughout the study.
Salivary antibody responses to cholera vaccine. ELISA (6) 675 ± 275C (6) 40 ± 20 (1) 140 ± 100 (2) 215 ± 440 (1) 21 (10) 1,175 ± 350d (10) 140 ± 140C (5) 475 ± 190-(4) 680 ± 480C (5) 28 (10) 1,100 ± 470d (9) 100 ± 220C (4) 370 ± 180C (4) 770 ± 650c (6) 35 (13) 700 ± 360C (10) 180 ± 115C (9) 233 ± 314 (3) 375 ± 300 (4) 44 (12) 1,450 ± 480d (12) 300 ± 210d (9) 535 ± 195c (7) 913 ± 436c (7) 56 (8) 580 + 270 (7) 175 ± 130d (5) 520 ± 223C (4) 880 ± 595C (5) a Days 14 and 28 correspond to the second and third oral vaccinations, respectively. b Antibody titers represent the reciprocal dilution of serum or saliva giving an ELISA absorbance value more than twice that of the control (no sample added). A significant increase in antibody titer was defined as greater than twofold. c P < 0.05. d p < 0.01.
analyses of parotid saliva specimens confirmed previous observations that peroral immunization with the cholera vaccine can result in increased IgA as well as IgG antibody levels in saliva (33) . Thus, although the specific salivary antibody titers did not increase significantly in the 2 weeks after the first immunization, there was a three-to fourfold geometric mean increase in titer in both IgG and IgA antitoxin levels after the second immunization and a fivefold rise after the third vaccination (Table 1) . Salivary IgA antitoxin titers were consistently higher than the corresponding IgG titers. Determinations of SFC in minor salivary glands revealed that the increase in salivary antitoxin antibodies was associated with an active B-cell response in minor labial salivary glands (Table 2) . However, the minor salivary gland-specific antitoxin SFC response was restricted to the IgA isotype (Table 2) immunization, at which time the blood SFC response had essentially disappeared. Furthermore, control salivary gland biopsies done before any intentional immunization were completely devoid of antitoxin SFC.
DISCUSSION
The finding that ingestion of antigens results in the selective induction of IgA antibodies in human external secretions (21) , together with data from animal studies showing migration of Peyer's patch B cells to various mucosal tissues (1), has suggested that antigen taken up by intestinal M cells sensitizes IgA-committed B-cell precursors which thereafter migrate to distant mucosal sites and generate local secretory IgA antibody responses (5) . Evidence for a common mucosal immune system in humans has been scanty because of the difficulty in demonstrating migratory behavior of mucosal B cells. Recent studies have demonstrated the transient appearance of antigen-specific IgA antibody-secreting cells in peripheral blood after mucosal immunization of humans (9, 15, 17, 39) . These observations provide support for the existence of a common mucosal immune system in humans, but the evidence remains indirect in the absence of demonstration of migration of gut-derived IgA precursors to nonintestinal mucosal or glandular tissues and of their differentiation there. The main finding of the present study is that following oral immunization of humans with the B subunitcontaining cholera vaccine, there was a substantial IgA antitoxin-producing cell response in minor salivary glands preceded by a brisk and transient specific SFC response in blood. In contrast to the blood SFC responses which comprised both IgG SFC and IgA SFC and to the serological responses which either were dominated by IgG antibodies (in serum) or consisted of both IgG and IgA (in parotid saliva), the SFC response in minor salivary glands was confined to the IgA isotype. This suggests marked differences in the migratory properties of IgA-and IgG-committed B cells activated at gut sites.
The extent to which IgG and IgA antitoxin antibodies detected in parotid saliva are locally synthetized and/or transferred from the intravascular pool is unknown. The fact that intravascular polymeric IgA is not efficiently transported into human parotid saliva, whereas a small fraction of IgG can transudate from plasma to saliva (16) , suggests that the anti-CT activity detected in parotid saliva is contributed by locally produced secretory IgA and serum-derived IgG. This interpretation is supported by other studies (24, 36) (18, 23) and may reflect local stimulation of minor salivary gland lymphoid tissue by environmental antigens present in the salivary ducts (25) .
While the serological antibody titers after immunization did not fluctuate much once they had been elevated (except for a slight additional increase with boosting), the kinetics of the cellular response was much more dramatic. In peripheral blood, there was an SFC peak 1 week after each of the vaccinations followed by a rapid decline until a new dose of vaccine was given. The (11) . On the basis of the present data, it seems reasonable that a similar response might also be achieved in humans with such conjugate vaccines. Our results therefore provide a basis for further efforts to prepare such conjugate vaccines for clinical trials in humans.
